ID   AGT2_RAT                Reviewed;         512 AA.
AC   Q64565; O08616; Q642F1;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   13-SEP-2005, sequence version 2.
DT   29-MAY-2024, entry version 156.
DE   RecName: Full=Alanine--glyoxylate aminotransferase 2, mitochondrial;
DE            Short=AGT 2;
DE            EC=2.6.1.44 {ECO:0000269|PubMed:2123486, ECO:0000269|PubMed:6803844};
DE   AltName: Full=(R)-3-amino-2-methylpropionate--pyruvate transaminase;
DE            EC=2.6.1.40 {ECO:0000269|PubMed:10989446, ECO:0000269|PubMed:2393662, ECO:0000269|PubMed:6803844};
DE   AltName: Full=Beta-ALAAT II {ECO:0000303|PubMed:2393662};
DE   AltName: Full=Beta-alanine-pyruvate aminotransferase;
DE            EC=2.6.1.18 {ECO:0000269|PubMed:10989446};
DE   AltName: Full=D-3-aminoisobutyrate-pyruvate aminotransferase {ECO:0000303|PubMed:2393662};
DE   AltName: Full=D-AIBAT {ECO:0000303|PubMed:10989446};
DE   AltName: Full=D-beta-aminoisobutyrate-pyruvate aminotransferase {ECO:0000303|PubMed:10989446};
DE   Flags: Precursor;
GN   Name=Agxt2; Synonyms=Agt2;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PARTIAL PROTEIN SEQUENCE.
RC   STRAIN=Wistar; TISSUE=Kidney;
RX   PubMed=7592550; DOI=10.1093/oxfordjournals.jbchem.a124787;
RA   Matsui-Lee I.S., Muragaki Y., Ideguchi T., Hase T., Tsuji M., Ooshima A.,
RA   Okuno E., Kido R.;
RT   "Molecular cloning and sequencing of a cDNA encoding alanine-glyoxylate
RT   aminotransferase 2 from rat kidney.";
RL   J. Biochem. 117:856-862(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 40-57, FUNCTION, CATALYTIC
RP   ACTIVITY, ACTIVITY REGULATION, BIOPHYSICOCHEMICAL PROPERTIES, SUBUNIT, AND
RP   COFACTOR.
RC   STRAIN=Sprague-Dawley; TISSUE=Liver;
RX   PubMed=10989446; DOI=10.1016/s0076-6879(00)24247-x;
RA   Tamaki N., Sakata S.F., Matsuda K.;
RT   "Purification, properties, and sequencing of aminoisobutyrate
RT   aminotransferases from rat liver.";
RL   Methods Enzymol. 324:376-389(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=6803844; DOI=10.1016/0304-4165(82)90054-x;
RA   Okuno E., Minatogawa Y., Kido R.;
RT   "Co-purification of alanine-glyoxylate aminotransferase with 2-
RT   aminobutyrate aminotransferase in rat kidney.";
RL   Biochim. Biophys. Acta 715:97-104(1982).
RN   [5]
RP   FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND
RP   DEVELOPMENTAL STAGE.
RX   PubMed=2393662; DOI=10.1016/0304-4165(90)90106-7;
RA   Ueno S., Sano A., Hineno T., Kondoh K., Mizuno T., Morino H., Kakimoto Y.;
RT   "Further studies on D-3-aminoisobutyrate-pyruvate aminotransferase.";
RL   Biochim. Biophys. Acta 1035:128-131(1990).
RN   [6]
RP   FUNCTION, CATALYTIC ACTIVITY, COFACTOR, SUBUNIT, SUBCELLULAR LOCATION,
RP   ACTIVITY REGULATION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=2123486; DOI=10.1016/s0021-9258(17)45307-5;
RA   Ogawa T., Kimoto M., Sasaoka K.;
RT   "Dimethylarginine:pyruvate aminotransferase in rats. Purification,
RT   properties, and identity with alanine:glyoxylate aminotransferase 2.";
RL   J. Biol. Chem. 265:20938-20945(1990).
CC   -!- FUNCTION: Multifunctional aminotransferase with a broad substrate
CC       specifcity (PubMed:10989446, PubMed:2123486, PubMed:2393662,
CC       PubMed:6803844). Catalyzes the conversion of glyoxylate to glycine
CC       using alanine as the amino donor (PubMed:2123486, PubMed:6803844).
CC       Catalyzes metabolism of not L- but the D-isomer of D-beta-
CC       aminoisobutyric acid to generate 2-methyl-3-oxopropanoate and alanine
CC       (PubMed:10989446, PubMed:2393662, PubMed:6803844). Catalyzes the
CC       transfer of the amino group from beta-alanine to pyruvate to yield L-
CC       alanine and 3-oxopropanoate (PubMed:10989446). Can metabolize NG-
CC       monomethyl-L-arginine (NMMA), asymmetric NG,NG-dimethyl-L-arginine
CC       (ADMA) and symmetric NG,N'G-dimethyl-L-arginine (SDMA)
CC       (PubMed:2123486). ADMA is a potent inhibitor of nitric-oxide (NO)
CC       synthase, and this activity provides mechanism through which the kidney
CC       regulates blood pressure (By similarity).
CC       {ECO:0000250|UniProtKB:Q9BYV1, ECO:0000269|PubMed:10989446,
CC       ECO:0000269|PubMed:2123486, ECO:0000269|PubMed:2393662,
CC       ECO:0000269|PubMed:6803844}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=glyoxylate + L-alanine = glycine + pyruvate;
CC         Xref=Rhea:RHEA:24248, ChEBI:CHEBI:15361, ChEBI:CHEBI:36655,
CC         ChEBI:CHEBI:57305, ChEBI:CHEBI:57972; EC=2.6.1.44;
CC         Evidence={ECO:0000269|PubMed:2123486, ECO:0000269|PubMed:6803844};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:24249;
CC         Evidence={ECO:0000305|PubMed:6803844};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(R)-3-amino-2-methylpropanoate + pyruvate = 2-methyl-3-
CC         oxopropanoate + L-alanine; Xref=Rhea:RHEA:18393, ChEBI:CHEBI:15361,
CC         ChEBI:CHEBI:57700, ChEBI:CHEBI:57731, ChEBI:CHEBI:57972; EC=2.6.1.40;
CC         Evidence={ECO:0000269|PubMed:10989446, ECO:0000269|PubMed:2393662,
CC         ECO:0000269|PubMed:6803844};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:18394;
CC         Evidence={ECO:0000305|PubMed:10989446};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=3-oxopropanoate + L-alanine = beta-alanine + pyruvate;
CC         Xref=Rhea:RHEA:14077, ChEBI:CHEBI:15361, ChEBI:CHEBI:33190,
CC         ChEBI:CHEBI:57966, ChEBI:CHEBI:57972; EC=2.6.1.18;
CC         Evidence={ECO:0000269|PubMed:10989446};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:14079;
CC         Evidence={ECO:0000305|PubMed:10989446};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=2-oxobutanoate + L-alanine = (2S)-2-aminobutanoate + pyruvate;
CC         Xref=Rhea:RHEA:77355, ChEBI:CHEBI:15361, ChEBI:CHEBI:16763,
CC         ChEBI:CHEBI:57972, ChEBI:CHEBI:74359; EC=2.6.1.44;
CC         Evidence={ECO:0000269|PubMed:2123486};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=N(omega),N(omega)-dimethyl-L-arginine + pyruvate = 5-(3,3-
CC         dimethylguanidino)-2-oxopentanoate + L-alanine; Xref=Rhea:RHEA:77303,
CC         ChEBI:CHEBI:15361, ChEBI:CHEBI:57972, ChEBI:CHEBI:58326,
CC         ChEBI:CHEBI:197301; Evidence={ECO:0000269|PubMed:2123486};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=N(omega),N('omega)-dimethyl-L-arginine + pyruvate = 5-(3,3'-
CC         dimethylguanidino)-2-oxopentanoate + L-alanine; Xref=Rhea:RHEA:77307,
CC         ChEBI:CHEBI:15361, ChEBI:CHEBI:57972, ChEBI:CHEBI:197308,
CC         ChEBI:CHEBI:197310; Evidence={ECO:0000269|PubMed:2123486};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=glyoxylate + N(omega),N(omega)-dimethyl-L-arginine = 5-(3,3-
CC         dimethylguanidino)-2-oxopentanoate + glycine; Xref=Rhea:RHEA:77311,
CC         ChEBI:CHEBI:36655, ChEBI:CHEBI:57305, ChEBI:CHEBI:58326,
CC         ChEBI:CHEBI:197301; Evidence={ECO:0000269|PubMed:2123486};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=glyoxylate + N(omega),N('omega)-dimethyl-L-arginine = 5-(3,3'-
CC         dimethylguanidino)-2-oxopentanoate + glycine; Xref=Rhea:RHEA:77315,
CC         ChEBI:CHEBI:36655, ChEBI:CHEBI:57305, ChEBI:CHEBI:197308,
CC         ChEBI:CHEBI:197310; Evidence={ECO:0000269|PubMed:2123486};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=N(omega)-methyl-L-arginine + pyruvate = 5-(3-methylguanidino)-
CC         2-oxopentanoate + L-alanine; Xref=Rhea:RHEA:77319, ChEBI:CHEBI:15361,
CC         ChEBI:CHEBI:57972, ChEBI:CHEBI:114953, ChEBI:CHEBI:197314;
CC         Evidence={ECO:0000269|PubMed:2123486};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=glyoxylate + N(omega)-methyl-L-arginine = 5-(3-
CC         methylguanidino)-2-oxopentanoate + glycine; Xref=Rhea:RHEA:77323,
CC         ChEBI:CHEBI:36655, ChEBI:CHEBI:57305, ChEBI:CHEBI:114953,
CC         ChEBI:CHEBI:197314; Evidence={ECO:0000269|PubMed:2123486};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-ornithine + pyruvate = 5-amino-2-oxopentanoate + L-alanine;
CC         Xref=Rhea:RHEA:77327, ChEBI:CHEBI:15361, ChEBI:CHEBI:46911,
CC         ChEBI:CHEBI:57972, ChEBI:CHEBI:58802;
CC         Evidence={ECO:0000269|PubMed:2123486};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=glyoxylate + L-ornithine = 5-amino-2-oxopentanoate + glycine;
CC         Xref=Rhea:RHEA:77331, ChEBI:CHEBI:36655, ChEBI:CHEBI:46911,
CC         ChEBI:CHEBI:57305, ChEBI:CHEBI:58802;
CC         Evidence={ECO:0000269|PubMed:2123486};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(2S)-2-aminobutanoate + glyoxylate = 2-oxobutanoate + glycine;
CC         Xref=Rhea:RHEA:77339, ChEBI:CHEBI:16763, ChEBI:CHEBI:36655,
CC         ChEBI:CHEBI:57305, ChEBI:CHEBI:74359;
CC         Evidence={ECO:0000269|PubMed:2123486};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=N(omega),N(omega)-dimethyl-L-arginine + oxaloacetate = 5-(3,3-
CC         dimethylguanidino)-2-oxopentanoate + L-aspartate;
CC         Xref=Rhea:RHEA:77343, ChEBI:CHEBI:16452, ChEBI:CHEBI:29991,
CC         ChEBI:CHEBI:58326, ChEBI:CHEBI:197301;
CC         Evidence={ECO:0000269|PubMed:2123486};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-alanine + oxaloacetate = L-aspartate + pyruvate;
CC         Xref=Rhea:RHEA:77347, ChEBI:CHEBI:15361, ChEBI:CHEBI:16452,
CC         ChEBI:CHEBI:29991, ChEBI:CHEBI:57972;
CC         Evidence={ECO:0000269|PubMed:2123486};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=2-oxobutanoate + N(omega),N(omega)-dimethyl-L-arginine = (2S)-
CC         2-aminobutanoate + 5-(3,3-dimethylguanidino)-2-oxopentanoate;
CC         Xref=Rhea:RHEA:77351, ChEBI:CHEBI:16763, ChEBI:CHEBI:58326,
CC         ChEBI:CHEBI:74359, ChEBI:CHEBI:197301;
CC         Evidence={ECO:0000269|PubMed:2123486};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=2-oxopentanoate + N(omega),N(omega)-dimethyl-L-arginine = 5-
CC         (3,3-dimethylguanidino)-2-oxopentanoate + L-2-aminopentanoate;
CC         Xref=Rhea:RHEA:77359, ChEBI:CHEBI:28644, ChEBI:CHEBI:58326,
CC         ChEBI:CHEBI:58441, ChEBI:CHEBI:197301;
CC         Evidence={ECO:0000269|PubMed:2123486};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=2-oxohexanoate + N(omega),N(omega)-dimethyl-L-arginine = 5-
CC         (3,3-dimethylguanidino)-2-oxopentanoate + L-2-aminohexanoate;
CC         Xref=Rhea:RHEA:77363, ChEBI:CHEBI:35177, ChEBI:CHEBI:58326,
CC         ChEBI:CHEBI:58455, ChEBI:CHEBI:197301;
CC         Evidence={ECO:0000269|PubMed:2123486};
CC   -!- COFACTOR:
CC       Name=pyridoxal 5'-phosphate; Xref=ChEBI:CHEBI:597326;
CC         Evidence={ECO:0000269|PubMed:10989446, ECO:0000269|PubMed:2123486};
CC   -!- ACTIVITY REGULATION: Inhibited by 5-fluorouracil and 6-fluorouracil
CC       (PubMed:10989446). Inhibited by phenylhydrazine, hydroxylamine, l-
CC       amino-L-proline, para-chloromercuribenzoate and HgCl2 (PubMed:2123486).
CC       {ECO:0000269|PubMed:10989446, ECO:0000269|PubMed:2123486}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.12 mM for D-beta-aminoisobutyrate {ECO:0000269|PubMed:10989446};
CC         KM=1.4 mM for beta-alanine {ECO:0000269|PubMed:10989446};
CC         KM=13.7 uM for N(omega),N('omega)-dimethyl-L-arginine (with pyruvate
CC         as cosubstrate) {ECO:0000269|PubMed:2123486};
CC         KM=11.1 uM for N(omega),N('omega)-dimethyl-L-arginine (with
CC         glyoxylate as cosubstrate) {ECO:0000269|PubMed:2123486};
CC         KM=9.7 uM for N(omega),N(omega)-dimethyl-L-arginine (with pyruvate as
CC         cosubstrate) {ECO:0000269|PubMed:2123486};
CC         KM=8.0 uM for N(omega)-methyl-L-arginine (with pyruvate as
CC         cosubstrate) {ECO:0000269|PubMed:2123486};
CC         KM=70 uM for L-ornithine (with pyruvate as cosubstrate)
CC         {ECO:0000269|PubMed:2123486};
CC         KM=7.8 uM for L-alanine (with glyoxylate as cosubstrate)
CC         {ECO:0000269|PubMed:2123486};
CC         KM=2.2 uM for pyruvate (with N(omega),N('omega)-dimethyl-L-arginine
CC         as cosubstrate) {ECO:0000269|PubMed:2123486};
CC         KM=2.4 uM for pyruvate (with N(omega),N(omega)-dimethyl-L-arginine as
CC         cosubstrate) {ECO:0000269|PubMed:2123486};
CC         KM=2.5 uM for pyruvate (with N(omega)-methyl-L-arginine as
CC         cosubstrate) {ECO:0000269|PubMed:2123486};
CC         KM=4.1 uM for pyruvate (with L-ornithine as cosubstrate)
CC         {ECO:0000269|PubMed:2123486};
CC         KM=2.9 uM for glyoxylate (with L-alanine as cosubstrate)
CC         {ECO:0000269|PubMed:2123486};
CC         KM=2.1 uM for glyoxylate (with N(omega),N('omega)-dimethyl-L-arginine
CC         as cosubstrate) {ECO:0000269|PubMed:2123486};
CC       pH dependence:
CC         Optimum pH is 9.5 for transamination between L-alanine and
CC         glyoxylate. Optimum pH is 10.0 for the transamination between
CC         dimethylarginines and pyruvate. Optimum pH is 10.5 for the
CC         transamination between L-ornithine and pyruvate.
CC         {ECO:0000269|PubMed:10989446, ECO:0000269|PubMed:2123486};
CC   -!- SUBUNIT: Homotetramer. {ECO:0000269|PubMed:10989446,
CC       ECO:0000269|PubMed:2123486}.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion {ECO:0000269|PubMed:2123486,
CC       ECO:0000269|PubMed:2393662}.
CC   -!- TISSUE SPECIFICITY: Expressed in the liver, lung and kidney.
CC       {ECO:0000269|PubMed:2123486, ECO:0000269|PubMed:2393662}.
CC   -!- DEVELOPMENTAL STAGE: Expression is low at birth, increases sharply
CC       thereafter for 10 days, and then subsequently declines to the adult
CC       level. {ECO:0000269|PubMed:2393662}.
CC   -!- SIMILARITY: Belongs to the class-III pyridoxal-phosphate-dependent
CC       aminotransferase family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D38100; BAA07281.1; -; mRNA.
DR   EMBL; AB002584; BAA19549.1; -; mRNA.
DR   EMBL; BC081765; AAH81765.1; -; mRNA.
DR   RefSeq; NP_114023.1; NM_031835.2.
DR   AlphaFoldDB; Q64565; -.
DR   SMR; Q64565; -.
DR   STRING; 10116.ENSRNOP00000024035; -.
DR   iPTMnet; Q64565; -.
DR   PhosphoSitePlus; Q64565; -.
DR   PaxDb; 10116-ENSRNOP00000024035; -.
DR   Ensembl; ENSRNOT00000024035.8; ENSRNOP00000024035.5; ENSRNOG00000017821.8.
DR   Ensembl; ENSRNOT00055046650; ENSRNOP00055038288; ENSRNOG00055026998.
DR   Ensembl; ENSRNOT00060035993; ENSRNOP00060029618; ENSRNOG00060020703.
DR   GeneID; 83784; -.
DR   KEGG; rno:83784; -.
DR   AGR; RGD:621767; -.
DR   CTD; 64902; -.
DR   RGD; 621767; Agxt2.
DR   eggNOG; KOG1404; Eukaryota.
DR   GeneTree; ENSGT00940000156125; -.
DR   HOGENOM; CLU_016922_8_0_1; -.
DR   InParanoid; Q64565; -.
DR   OMA; MVPGFKY; -.
DR   OrthoDB; 345661at2759; -.
DR   BRENDA; 2.6.1.40; 5301.
DR   BRENDA; 2.6.1.44; 5301.
DR   Reactome; R-RNO-389661; Glyoxylate metabolism and glycine degradation.
DR   SABIO-RK; Q64565; -.
DR   PRO; PR:Q64565; -.
DR   Proteomes; UP000002494; Chromosome 2.
DR   Bgee; ENSRNOG00000017821; Expressed in adult mammalian kidney and 11 other cell types or tissues.
DR   GO; GO:0005759; C:mitochondrial matrix; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0047305; F:(R)-3-amino-2-methylpropionate-pyruvate transaminase activity; IDA:UniProtKB.
DR   GO; GO:0008453; F:alanine-glyoxylate transaminase activity; IDA:UniProtKB.
DR   GO; GO:0016223; F:beta-alanine-pyruvate transaminase activity; IDA:UniProtKB.
DR   GO; GO:0030170; F:pyridoxal phosphate binding; IEA:InterPro.
DR   GO; GO:0019265; P:glycine biosynthetic process, by transamination of glyoxylate; ISO:RGD.
DR   GO; GO:0009436; P:glyoxylate catabolic process; ISO:RGD.
DR   GO; GO:0019481; P:L-alanine catabolic process, by transamination; ISO:RGD.
DR   GO; GO:2001299; P:N(omega),N(omega)-dimethyl-L-arginine catabolic process; IDA:UniProtKB.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; ISO:RGD.
DR   CDD; cd00610; OAT_like; 1.
DR   Gene3D; 3.90.1150.10; Aspartate Aminotransferase, domain 1; 1.
DR   Gene3D; 3.40.640.10; Type I PLP-dependent aspartate aminotransferase-like (Major domain); 1.
DR   InterPro; IPR005814; Aminotrans_3.
DR   InterPro; IPR049704; Aminotrans_3_PPA_site.
DR   InterPro; IPR015424; PyrdxlP-dep_Trfase.
DR   InterPro; IPR015421; PyrdxlP-dep_Trfase_major.
DR   InterPro; IPR015422; PyrdxlP-dep_Trfase_small.
DR   PANTHER; PTHR45688; ALANINE--GLYOXYLATE AMINOTRANSFERASE 2, MITOCHONDRIAL; 1.
DR   PANTHER; PTHR45688:SF3; ALANINE--GLYOXYLATE AMINOTRANSFERASE 2, MITOCHONDRIAL; 1.
DR   Pfam; PF00202; Aminotran_3; 1.
DR   PIRSF; PIRSF000521; Transaminase_4ab_Lys_Orn; 1.
DR   SUPFAM; SSF53383; PLP-dependent transferases; 1.
DR   PROSITE; PS00600; AA_TRANSFER_CLASS_3; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Aminotransferase; Direct protein sequencing; Mitochondrion;
KW   Pyridoxal phosphate; Reference proteome; Transferase; Transit peptide.
FT   TRANSIT         1..39
FT                   /note="Mitochondrion"
FT                   /evidence="ECO:0000269|PubMed:10989446"
FT   CHAIN           40..512
FT                   /note="Alanine--glyoxylate aminotransferase 2,
FT                   mitochondrial"
FT                   /id="PRO_0000001270"
FT   MOD_RES         55
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q3UEG6"
FT   MOD_RES         69
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q3UEG6"
FT   MOD_RES         69
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q3UEG6"
FT   MOD_RES         82
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q3UEG6"
FT   MOD_RES         260
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q3UEG6"
FT   MOD_RES         260
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q3UEG6"
FT   MOD_RES         302
FT                   /note="N6-succinyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q3UEG6"
FT   MOD_RES         348
FT                   /note="N6-(pyridoxal phosphate)lysine"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         415
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q3UEG6"
FT   MOD_RES         415
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q3UEG6"
FT   MOD_RES         418
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q3UEG6"
FT   MOD_RES         418
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q3UEG6"
FT   MOD_RES         452
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q3UEG6"
FT   CONFLICT        305
FT                   /note="F -> L (in Ref. 1; BAA07281)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        332
FT                   /note="W -> Y (in Ref. 1; BAA07281)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        337..338
FT                   /note="HD -> QA (in Ref. 1; BAA07281)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        435..436
FT                   /note="MV -> WW (in Ref. 1; BAA07281)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        494..496
FT                   /note="FAF -> LAL (in Ref. 1; BAA07281)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   512 AA;  57201 MW;  C35E389789516B5C CRC64;
     MSLAWRTLQK AFYLETSLRI LQMRPSLSCA SRIYVPKLTL HTKHNMPPCD FSPEKYQSLA
     YNHVLEIHKQ HLSPVNTAYF QKPLLLHQGH MEWLFDSEGN RYLDFFSGIV TVGVGHCHPK
     VTAVAKKQMD RLWHTSSVFF HSPMHEYAER LSALLPEPLK VIFLVNSGSE ANDLAMVMAR
     AYSNHTDIIS FRGAYHGCSP YTLGLTNVGI YKMKVPSTIA CQSTMCPDVF RGPWGGSHCR
     DSPVQTVRKC SCAPDGCQAK ERYIEQFKDT LNTSVATSIA GFFAEPIQGV NGVVQYPKEF
     LKEAFALVRE RGGVCIADEV QTGFGRLGSH FWGFQTHDTM PDIVTMAKGI GNGFPMAAVV
     TTPEIASSLA KHLHHFSTFG GSPLACAIGS AVLEVIEEEN LQRNSQEVGT YMLLKFAKLR
     DEFDIVGDVR GKGLMVGIEM VQDKISRQPL PKTEVNQIHE DCKDMGLLVG RGGNFSQTFR
     IAPPMRVTKL EVDFAFEVFR SALTQHMERR AK
//
